**Name of Journal:** *World Journal of Gastroenterology*

**ESPS manuscript number: 20815**

**Manuscript type: TOPIC HIGHLIGHT**

**2015 Advances in Inflammatory Bowel Disease**

**Th17 plasticity and its changes associated with inflammatory bowel disease**

Ueno A *et al.* Th17 plasticity in IBD

Aito Ueno, Abhisek Ghosh, Daniel Hung, Ji Li, Humberto Jijon

**Aito Ueno, Daniel Hung, Humberto Jijon,** Department of Medicine, University of Calgary, Calgary T2N 1N4, Alberta, Canada

**Abhisek Ghosh,** Darent Valley Hospital, Dartford, DA2 8DA Kent, United Kingdom

**Ji Li,** Department of Gastroenterology, Peking Union Hospital, Beijing 100730, China

**Author** **contributions**: The listed authors solely contributed to this manuscript in writing and searching the literatures

**Conflict-of-interest statement:** The authors have no conflict of interest to report in this work.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Dr. Aito Ueno**, Department of Medicine, University of Calgary, HSC1838, 2500 University Dr. NW, Calgary, Alberta T2N 1N4, Canada. [aueno@ucalgary.ca](mailto:aueno@ucalgary.ca)

**Telephone:** +1-403-2206603

**Fax:** +1-403-2109157

**Received:** June 23, 2015

**Peer-review started:** June 26, 2015

**First decision:** July 20, 2015

**Revised:** August 17, 2015

**Accepted:** October 23, 2015

**Article in press:**

**Published online:**

**Abstract**

CD4 T helper (Th) cell differentiation into distinct T cell subsets is critical to the normal function of the immune system. Until recently, the paradigm held that naïve T cells differentiated into distinct subsets under the guidance of environmental cues (*e.g.,* cytokines) and that once polarized, these cells were committed to a particular functional state. However, the existence of transdifferentiated T cell populations, which express signature transcription factors and cytokines associated with more than one Th subset, challenges the immutability of T helper subsets and suggests that plasticity is a feature of multifaceted immune responses. How this process impacts immune dysregulation in diseases such as inflammatory bowel diseases (IBD) and the machinery that underlies this process is far from fully understood. Interleukin (IL)-17 secreting helper T (Th17) cells have been heavily implicated in tissue-specific immune pathology including murine models of IBD, human Crohn’s disease and ulcerative colitis. Plasticity within this subset is suggested by the existence of IL-17 secreting cells, which, can also secrete interferon-γ, the signature cytokine for Th1 cells or, can co-express the anti-inflammatory transcription factor Foxp3, a signature transcription factor of regulatory T cells. In this review we mainly discuss evidence for Th17 plasticity, mechanisms, which govern it, and highlight the potential to therapeutically target this process in human IBD.

**Key words:** Th17; Regulatory T cells; T cell plasticity; Inflammatory bowel disease

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Recently, two innovative clinical failures in inflammatory bowel disease which sought to manipulate T helper (Th) subsets *via*  either transplantation of regulatory T cells or interleukin-17 blockade using secukinumab, suggest that altering the balance between inflammatory and regulatory subsets in inflammatory bowel diseases (IBD) may be more complex than previously thought. One reason may be the flexible nature of T helper subset commitment, otherwise referred to as plasticity. Here we discuss plasticity between regulatory and inflammatory subsets in T helper CD4+ cells, especially Th17 cell subset, and the potential to therapeutically target this process in human IBD.

Ueno A, Ghosh A, Hung D, Li J, Jijon H. Th17 plasticity and its changes associated with inflammatory bowel disease. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

The spectrum of immune-mediated disease encompasses a wide variety of chronic inflammatory conditions such as inflammatory bowel disease (IBD) comprised of Crohn’s disease (CD), and ulcerative colitis (UC) as well as rheumatoid arthritis (RA), multiple sclerosis (MS), and psoriasis. Although the underlying triggers remain poorly understood, it is now clear that T cells are essential to the development and perpetuation of these diseases[1-3]. Since the landmark description of functionally distinct T helper 1 (Th1) and Th2 CD4**+** effector subsets, each with unique cytokine profiles[4], much work has focussed on dissecting their roles in both health and disease. The spotlight has recently been drawn to a novel subset, the Th17 cell, so named due to its ability to secrete interleukin (IL)-17A, which has emerged as a major player in tissue-specific immune pathology. The initial emphasis on the detrimental effects of Th17 is reflected by the plethora of early literature supporting such a role in both human and murine studies[5-10]. However, a growing body of evidence now suggests essential protective roles, particularly in the context of mucosal integrity and defence against extracellular pathogens[5,11-16]. Th17 cells and their associated cytokines have been found to interact more closely with other adaptive immune cells than previously thought, raising interesting questions about how to select and design therapeutic strategies targeting this cell population[2,17]. New technologies such as transcriptome profiling, global epigenetic mapping and computerized simulation analysis[18,19] have captured a more accurate picture of this T cell subset revealing it to be more transient, complex and perhaps more reversible than previously imagined. In addition to a well-established role in extracellular pathogen clearance, Th17 cells can also participate in intracellular pathogen clearance *via*  unconventional IFN-γ secretion[20,21]. Human Foxp3+ regulatory T cells (Treg) can differentiate into IL-17 promoting cells *in vitro*[22]. Flexibility within this subset may allow Th17 cells to embrace pro-inflammatory and protective roles in mucosal immunity by secreting a spectrum of cytokines without requiring *de novo* differentiation of naïve T cells. Likewise, Th17 cells may be generated quickly from regulatory T cells (Treg) in order to defend from acute invasion of pathogens. This ability to transition between functional states is defined as T cell plasticity.

This review mainly focuses on human studies and outlines the major features of Th17 plasticity including the Treg/Th17 paradigm shift in the context of IBD and in the maintenance of intestinal homeostasis.

**CHARACTERISATION OF TH17 AND TREG SUBSETS IN IBD**

In the last 15 years or so, the focus of attention regarding T cell subsets has shifted from the classical Th1/Th2 paradigm to that of Th17/Treg. This has indeed been the case in IBD.

The discovery of extrathymic Treg development in the intestine has attracted enormous attention and highlights the importance of Treg cells in intestinal homeostasis. Hori *et al*[23]*,* demonstrated that co-transfer of peripherally generated forkhead box p3 (Foxp3) positive Treg cells could attenuate disease in the adoptive transfer model of mouse colitis. Shortly after this study, Makita *et al*[24]*,* showed the intestinal prevalence of Treg in patients with IBD. Mucida *et al*[25]*,* have sinceidentified retinoic acid, derived from vitamin A and metabolized by dendritic cells, as a key signal regulating Foxp3 expression by naïve T cells in response to TGF-β. Overall, the digestive tract requires high levels of inducible Treg cells in order to preserve tolerance to the enormous antigenic burden comprised by commensal flora and dietary antigens[26].

At around the same time, Fujino *et al*[27]*,* first reported on the prevalence of Th17 cells in patients with IBD. Patients with UC and CD show increased IL-17A levels in serum and mucosa[17]and an IL-17A gene polymorphism has been linked to UC susceptibility[28]. This cytokine, in addition to promoting barrier function, is a potent promoter of granulopoiesis and neutrophil chemotaxis and plays an important role in the clearance of extracellular bacterial and fungal infections[29]. Recently, Ciofani *et al*[30] have described an intracellular network regulating Th17 specification. Interestingly, genome-wide association studies linked at least 24 loci within this network to single nucleotide polymorphisms (SNPs) associated with ulcerative colitis and Crohn’s disease, highlighting the importance of this T cell subset towards the pathogenesis of IBD[30,31].

***IL-17 secreting Th17 subset***

Intestinal effector T cells arise from naïve lymphocytes derived from the thymus, which then undergo functional differentiation in the intestinal mucosa upon encountering their cognate antigen displayed by activated antigen-presenting cells (APCs). APCs and potentially other cells release cytokines, which act in combination with environmental cues, including bacterial and dietary products as well as salt concentration[32,33], thereby activating the Jak-STAT and other signalling pathways to exert their biological functions.

Differentiation of Th17 cells is exclusively dependent on signal transducer and activator of transcription 3 (STAT3)[34] and crucially requires the expression of the transcription factor retinoic acid receptor-related orphan receptor γ thymus in mouse (RORγt)[35]. Studies in the mouse and *in vitro* human cell cultures have revealed the critical roles of transforming growth factor β1 (TGF-β1) alongside IL-6[36-38], IL-1β[39] and IL-21[40] in Th17 polarization. IL-23, secreted mainly by innate myeloid cells including activated dendritic cells (DC), monocytes and macrophages, is critical for Th17 proliferation and maintenance, though dispensable for the initiation of Th17 development. Importantly, mutations within the *il23r* locus, which encodes a receptor subunit unique to IL-23, are associated with psoriasis[41], ankylosing spondylitis[42] and IBD[43,44].

Whilst Th17 cells are distinguished by IL-17A production, they are also capable of producing other cytokines, including but not limited to IL-17F, IL-21 and IL-22. IL-17F, a member of the IL-17 family, may also have dual roles in the context of mucosal disease. In the DSS model of IBD, IL-17F-/- mice show less severe disease than wild-types[28]. IL-17F evidently appears to have a distinct set of roles, despite structural similarity to IL-17A, and further research will be necessary to establish its specific importance. Substantial evidence exists for pathogenic roles of IL-22, particularly in the context of psoriasis[45]. However, IL-22 may play a critical role in the maintenance of the intestinal epithelial barrier and in mucosal healing[45]. It is thus important to emphasize that although Th17 cells are defined by their expression of IL-17 and RORc, human counterpart of RORγt, these cells likely express heterogeneous cytokine profiles, at times simultaneously expressing both protective (IL-22) and deleterious (IL-17A, IFN-γ) cytokines in a tissue-temporal specific manner[5]. In addition, the unexpected failure of secukinumab[46], a human anti-IL-17 monoclonal antibody, in the treatment of Crohn’s disease reflects the complex role of IL-17 and the heterogeneous causes of the disease [47].

***Foxp3+ Treg subset***

In contrast, anti-inflammatory Foxp3-expressing Treg cells play an important role in tissue homeostasis *via*  controlling pro-inflammatory effector T cells. Treg cells were first described as “self”-recognising T cells which develop in the thymus. Nowadays this population of Treg cells has come to be referred to as naturally occurring Treg (nTreg)[48]. Initially, Treg cells were believed to differentiate along a distinct pathway to that of conventional T cells which arise from naïve T cells in the periphery (extra-thymically). It is now apparent however that naïve progenitor T cells can give rise to a population of anti-inflammatory Foxp3 expressing T cells extra-thymically. This population is referred to as inducible Treg (iTreg)[48]. The major residential and developmental organs of iTreg cells are in fact the gut mucosa and mesenteric lymph nodes. Differentiation of iTreg cells is dependent on STAT5 and requires activation of the lineage-specifying transcription factor Foxp3. *in vitro* studies using human cells have revealed the critical roles for TGF-β1, together with the cofactor retinoic acid in iTreg development from naïve Th cells[49].

***Similarities and differences between Th17 and Treg development***

Interestingly, both Th17 and iTreg cells share essential developmental cues, and thus similar developmental pathways, as both subsets can be generated under the influence of TGF-β1. However additional signals specify development of each subset. Similar to Th1 and Th2 subsets, Th17 and Treg can negatively influence each other. In mice, increasing concentrations of TGF-β1 are associated with increased Foxp3 levels and decreased IL-23R expression, leading to decreased IL-23-dependent maintenance of Th17 cells and resulting in impaired Th17 development[50]. In addition, Foxp3 was found to directly inhibit IL-17 expression. As a result, Foxp3 and RORγt double expressing T cells in the lamina propria produced lower levels of IL-17 compared to T cells expressing RORγt alone[50]. Smad 2, 3, and 4, which transduce the extracellular TGF-β1 signal to the nucleus, are pivotal to iTreg generation whilst dispensable for Th17 development[51,52].

Gut resident and pathogenic microbes contribute to gut homeostasis and disease in part by shaping Th subset polarization. Interestingly, Th17 cells are induced by components of the intestinal flora, as has been shown for segmented filamentous bacteria (SFB)[53]. This requires MHC class II-dependent presentation of SFB antigens by DCs. On the other hand, commensal bacteria are known to influence gut tolerance by generating Treg cells specific to themselves. Transplantation of specific *Clostridia* clusters into germ free mice induces increased colonic Tregcells[54,55]. *Lactobacillus reuteri* colonization is also associated with an increase in gut residential Tregcells[56]. Interestingly, bacterial fermentation products may also play an important role in Treg generation. The short-chain fatty acids (SCFAs) can promote DC tolerance along with generation of colonic Tregcells[57,58]. Another bacterial product, polysaccharide A (PSA) from *Bacteroides fragilis* can induce anti-inflammatory Foxp3+, IL-10 secreting Treg cells *via*  TLR2 signalling[59]. Thus, intestinal dietary and commensal products can influence Treg and Th17 development.

**MECHANISMS OF PLASTICITY AND RECIPROCAL REGULATION BETWEEN TREG AND TH17 SUBSET**

There are at least four major pathways and/or factors which contribute to Th17 plasticity. The cytokine milieu directs T cell subset development and also induces plasticity *via*  the activation of different and specific STAT molecules and multiple transcription factors. Furthermore, it has emerged that immune-regulatory micro RNA (miR) plays a fundamental role in controlling gene expression, thus influencing T cell fate and plasticity. There is also the unique role of aryl hydrocarbon receptor (AhR) and its environmental and physiological ligands alongside histone methylation and epigenenetic modifications which may fundamentally influence T cell plasticity. Figure 1 summarizes the concept of Th17 plasticity.

***Cytokine pathways (main contributor to plasticity*)**

As described above, TGF-β signalling with the additional influence of IL-1β, IL-6 and IL-21 are critical to Th17 lineage development as well as the role of IL-23 signalling for the maintenance and function of this subset. High concentrations of exogenous Th17-generating cytokines are able to convert Foxp3+ Treg cells into IL-17 secreting Th cells *in vitro*. Since cytokine secretion is a final step in lineage differentiation, this population is considered to possess two signature features for two different subsets; Foxp3 for Treg, and IL-17 for Th17. We found increased levels of circulating IL-17 and Foxp3 double expressing T cells in IBD patients compared to healthy controls. Furthermore, we demonstrated the conversion of CD25**+** CD45RO**-** Treg cells from peripheral blood of IBD patients into IL-17 secreting Foxp3 expressing cells as well as RORc and Foxp3 expressing cells in the presence of combinations of the above mentioned cytokines[60]. Comparing the *in vitro* generation of double expressing cells in two types of IBD patients, CD patients have a higher prevalence of double expressing cells generated in the presence of IL-1β/TGF-β/IL-6 than UC while UC patients have an increased frequency of this population in response to IL-21/IL-23 than CD samples, suggesting disease-associated plasticity of Th cells in IBD[60]. A recent elegant study by Basu *et al.,* revealed that IL-1 signalling represses SOCS3, an inhibitory molecule of STAT3 altering the STAT3/STAT5 balance resulting in Th17 generation. This model offers an explanation for why exogenous IL-1β converts Foxp3+ Treg cells into IL-17**+** Foxp3**+** double expressing Th cells[61].

Cytokines which induce Th17 development and plasticity are summarised in Table 1[62-69].

***Transcription factors***

There is now vast literature detailing multiple transcription factors and their relationship to T cell plasticity. These transcription factors directly regulate and/or promote gene expression by binding to their promoter regions in order to contribute to the multifaceted nature of T cell subsets.

Ciofani *et al*[30] recently identified FOS-like antigen 2 (Fosl2) as a key determinant of Th17 plasticity in their remarkable study of Th17 cell specification[30]. *in vitro* differentiation of mouse CD4 T cells deficient in Fosl2 under Th17 polarizing conditions yielded IL-17 producing cells which co-expressed Foxp3. Interestingly, Fosl2 deficiency also enabled IFN-γ production in Th17 and Th2 cultures, particularly when Th17 cells were subsequently exposed to Th1-skewing conditions.

Interferon regulatory factor 4 (IRF4) is a transcription factor expressed in hematopoietic cells and plays pivotal roles in the immune response. IRF4 levels were augmented in patients with active inflammatory bowel disease and correlated with enhanced production of IL-17 and IL-22 mRNA[70]. On the other hand, lack of IRF4 seems to cause resistance to Th17-mediated autoimmune diseases[71]. Basic leucine zipper transcription factor, BATF, along with IRF4, was recently proposed as a 'pioneer factor' in T cells[30]. After T cell receptor (TCR) ligation, BATF expression is rapidly induced in naïve T cells. The BATF-JUN heterodimer and IRF4 bind to the same regulatory regions to mediate chromatin remodelling and facilitate accessibility to regulatory elements by other Th cell subset-specific transcription factors including STAT3, MAF and RORγt in Th17. Interestingly, BATF and IRF4 are also necessary for Treg differentiation in visceral adipose tissue through direct regulation of IL-33 receptor, ST2 and PPAR-γ expression[72]. BATF**+** RORc**-** Th17 cells are found in gut tissues from UC but not CD patients[73]. Taken together BATF/IRF4 axis may direct Treg/Th17 balance and plasticity in the gut.

A member of the Ikaros family, IKZF3 (or Aiolos) is known to promote Th17 differentiation by supressing IL-2 production[74]. Interestingly, IKZF3 is also expressed in iTreg lacking the expression IKZF2, (or Helios). These IKZF2**-** IKZF3**+** Foxp3**+** Th cells express IL-17 and exert reduced regulatory functions in healthy human blood samples[75]. Furthermore, polymorphism in *Ikzf3* locus shows an association with CD and UC[31]. Thus, IKZF3 may turn out to be an important regulator of Th17-Treg plasticity in IBD.

An environmental sensor, Hypoxia-inducible factor 1 (HIF-1), which is induced by Th17 cells to promote signalling in a Stat3-dependent manner, cooperates with RORγt to control expression of Th17 genes, such as IL-17A, IL-17F, and IL-23R. Furthermore, HIF-1 negatively regulates Treg development by mediating Foxp3 protein degradation[33].

On the other hand, Liu et al. recently reported that TGF-β and IL-6 regulate Th1 cell conversion into the Th17 subset *via*  expression of Runx1. This is supported by the finding that siRNA mediated silencing of Runx1 inhibits this conversion. Furthermore, TGF-β enhanced histone H3K9 acetylation but inhibited H3K9 trimethylation of Runx1- and ROR-γt-binding sites on the *il-17* or *rorc* gene in Th1 cells in this disease model[76].

Transcription factors which are critical for Th17 development and plasticity are summarised in Table 2.

***Micro-RNA (a cause of plasticity)***

Micro RNA (miR) are small fragments of non-coding RNA (mostly 17~22 nucleotides) that act as regulators of RNA expression through binding to the 3’-UTR of complementary mRNA resulting in repression/silencing of target RNAs. Several miRs have been reported to influence the differentiation of Th cell subsets[77] as well as plasticity and reciprocal regulation among Th cell subsets[78].

Targeting STAT1, which is required for optimal Th1 development, miR146a plays an essential role in Treg function and development[78]. Targeting suppressor of cytokine signalling 1 (SOCS1), an inhibitor of STAT1, 4, and 5, miR155 plays an unique role in the development of Th1, Th2, and Treg cells and conversely in the suppression of Th17 differentiation. Targeting of PIAS3, an antagonist of STAT3, miR301 influences Th17 expansion[78]. Interestingly, the miR146a and miR155 are induced by toll-like receptors, well-known bacterial sensors, suggesting a critical involvement of micro-organisms[79]. Moreover, NOD2, a bacterial sensor closely linked to the pathogenesis of Crohn’s disease, induces miR29 resulting in downregulation of IL-23 secretion by dendritic cells through targeting of IL-12p40 and IL-23p19. This, in turn, was shown to suppress RORγt expression in the DSS mouse model of colitis[80].

In activated T cells, miR-210, which targets HIF-1, is upregulated 100 fold. This is especially notable in Th17 cells, resulting in decreased HIF-1α expression. Deletion of *Mir210* promotes Th17 differentiation under hypoxic conditions. In experimental colitis, miR210 reduced the abundance of *Hif1a* transcripts and the proportion of cells that produced inflammatory cytokines resulting in decreased disease severity[81]. Induced by natural and environmental ligands of the aryl hydrocarbon receptor, the miR132/212 cluster promotes Th17 development[82]. The mechanisms of Th plasticity in aryl hydrocarbon receptor signalling will be described in the next section of this review.

Targeting EST1 which is a negative regulator of Th17 cells, miR326 is critical for Th17 differentiation. Furthermore, miR10, which is selectively expressed in Treg and induced by TGF-β signalling together with retinoic acid, can limit Th17 differentiation and furthermore can convert conventional Th cells into iTreg. The contribution of this miRNA to Treg stability is highly dependent on Foxp3 expression yet not responsible for Foxp3 induction[78]. A regulator of the suppressive activity of Treg cells, miR-126 leads to enhanced Foxp3 expression by targeting PIK3R2, a regulatory component of PI3K which downregulates Foxp3 induction[83]. The cluster of miR17~92, a complex of 6 miRNAs, influences Treg function *in vitro* resulting in the generation of IL-10 secreting Foxp3+ T cells. Although miR17 specifically targets TGFβ receptor II and Creb1, the targets of other parts of this cluster are still unknown[78].

Interestingly, deletion of critical compounds for miR signalling, such as DICER or DROSHA which are found in the micro RNA biogenesis pathways, showed that Treg-specific micro RNA expression is required to suppress T effector cells and maintain tolerance, suggesting that lack of Treg-specific miR results in immune-dysregulation[78].

Since miRs directly regulate the expression of many genes essential to Treg and Th17 subsets, it is highly likely they contribute to Th17-Treg plasticity. However, this exciting field is still in its infancy and further studies are undeniably required.

MicroRNA which influence Th17 development and plasticity are summarised in Table 3.

***Aryl hydrocarbon receptor (unique mechanistic role of a receptor with dual functions)***

The Aryl hydrocarbon receptor (AhR) first came to attention1970-80s[84,85] as a receptor for a recognized carcinogen, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD). This receptor is a ligand-activated transcription factor, which is responsible for the regulation of several xenobiotic response genes, such as the cytochrome P450 family[86]. Soon, attention shifted to the contribution of this receptor to oncogenesis *via*  the suppression of immune-surveillance in response to TCDD, suggesting a TCDD-induced immune regulatory function of AhR pathways[87]. Later, 6-formylindolo [3,2-b] carbazole (FICZ) was recognised as an endogenous ligand of AhR; however the function of the receptor bound to FICZ was not the same as that bound to TCDD, suggesting that this receptor has ligand specific functions[88]. In regard to T cell polarization, Quintana *et al.,* discovered that activation of the AhR with TCDD leads to the generation of Tregs[89], and in the same issue of Nature, Veldhoen *et al*[90]*,* reported alternative activation with FICZ leading to Th17 cell differentiation. The effect on Th17 generation has been confirmed by subsequent studies in vitro and in vivo[91,92], while the influence on Treg generation has been more controversial[93]. Recently, Mezrich *et al*[94]*,* showed evidence for a missing link in AhR-derived Treg generation in that kynurenine, a metabolite in the indoleamine 2,3-dioxygenese (IDO) dependent tryptophan degradation pathway, is a key ligand of AhR[94,95]. IDO is an enzyme known to suppress effector T cells and is expressed in regulatory plasmacytoid dendritic cells in response to IFN-γ. This kynurenine bound AhR generates Treg *via*  influencing the TGF-beta signalling pathway[94]. Furthermore, Moura-Alves *et al*[96]*,* has reported that AhR binds pathogen-associated molecular patterns (PAMPs), regulating immunity in response to bacteria. Although this observation was limited to myeloid and epithelial cells from lung in a murine infectious model, there is a possibility that bacterial activation of AhR may modulate development of Th subsets in a complex bacterial environment, such as the digestive tract.

Taken together one can speculate that a unique function of AhR may be to contribute to plasticity between the Treg and Th17 subsets *via*  differential binding to environmental or physiological ligands including bacteria-derived metabolites and PAMPs.

Figure 2 illustrates the contributing factors to the plasticity between Treg and Th17.

***Histone methylation (monitoring the characteristics of plasticity)***

Histone modifications including acetylation, methylation, and phosphorylation, are associated with gene expression or repression *via*  alternations in chromatin structure[77]. In regard to Th1, Th2 and Th17 subset development, trimethylation of lysine 4(H3K4me3) and lysine 27(H3K27me3) play important roles in activation and repression, respectively, of gene expression downstream of transcription factors specific to Th subsets. Thus, monitoring H3K4me3 and H3K27me3 status can visualize the potential for plasticity in T cell subsets.

H3K4me3 marks the signature cytokine genes (*Ifng* for Th1, *Il4* for Th2, *Il17a*) within the Th17 subset while repressive H3K27me3 is found on Th17 signature cytokine genes in Th1 (*Il4, Il17a*), Th2 (*Ifng, Il17a*) and Th17 (*Il4, Ifng*), suggesting lineage commitment to these particular subsets within these cells. Interestingly however, trimethylation on some transcription factor genes is bivalent (both H3K4 and H3K27) suggesting an element of reversibility in epigenetic status, particularly in Th17 cells. In these cells it is possible to find bivalent methylation in the Th1 transcription factor *Tbx21* and Th2 transcription factor *Gata3*, in addition, Foxp3 may remain unmethylated suggesting a “neutral” state. Thus, histone methylation states may help explain why Th17 cells can swing to other subsets more easily than other T cell subsets[97-99]. Cytokines regulate the trimethylation status of Th17, resulting in subset conversion and plasticity. Also, the universal bivalent status of Tbx21 in all Th subsets except Th1, where you have only permissive H3K4me3, explains why plasticity towards the Th1 subset is dominant[99]. Thus, monitoring trimethylation status of H3K4 and H3K27 is useful in predicting the potential for, and direction of Th cell plasticity.

A histone modifying enzyme, JMJD3 is a histone H3K27 demethylase[100]. Li *et al*[101]*,* reported that JMJD3 ablation promoted Th cell differentiation into Th2 and Th17 cells in the small and large intestines, and inhibited T-cell differentiation into Th1 cells *in vitro* and in a Th1-dependent colitis model. JMJD3 deficiency also restrains plasticity of Th2, Th17 and Treg cells towards Th1 cells. The skewing of T-cell differentiation is concomitant with changes in the expression of key transcription factors and cytokines *via*  changes in H3K27me3 and H3K4me3 levels[101].

**TH17 PLASTICITY IN CHRONIC INFLAMMATORY DISEASES INCLUDING IBD**

IFN-γ+ IL-17+ double expressing cells are considered a cross-over transition of Th17 into Th1 lymphocytes[102]. This cell population represents an efficient local host defense system which shifts host defense from extracellular pathogens to intracellular microbial infections[103] and may contribute to autoimmune pathogeneses in both mouse models and in human diseases[104,105]. Globig *et al*[106]*,* suggested that this population is indeed a subpopulation of Th17 cells and may be involved in IBD pathogenesis of both CD and UC. Interestingly, Weaver and colleagues recently have provided evidence that Th17 cells can act as precursors for IFN-γ secreting Th1 cells in a mouse of colitis, showing the indispensability of Th17/Th1 plasticity in the pathogenesis of colitis[21].

Likewise, IL-17+ Foxp3+ double expressing CD4+ T cells may differentiate into Th17 cells under pro-inflammatory conditions such as IL-1β, IL-6, IL-21, IL-23 and TGF-β**+**, having as yet largely unknown consequences for human disease initiation or progression[107]. On the other hand, plasticity from Th17 to Treg has not been frequently reported. However, a recent study from Yale University, suggests that this can in fact occur in the context of intestinal immune responses. According to their findings, Th17 cells generated during bacterial infection can be converted into IL-10high, Foxp3lo Tr1-like regulatory T cells. This was dependent on TGF-β1 and could be enhanced *in vitro* using an AhR ligand, FICZ[108]. This suggests that Th17 cells may alter their inflammatory status during infection, thus quenching inflammation and suggests possible avenues *via*  which this mechanism could be harnessed therapeutically[108].

The Th17-promoting cytokine, IL-23 is known to play an essential role in driving intestinal inflammation. This cytokine also plays an inhibitor role in augmentation of intestinal iTreg generation[109]. Furthermore, IL-23 together with IL-12 signalling promotes IFN-γ secretion from Th17 in intestine, leading Th17/Th1 plasticity[110]. IL-23 signalling pathway is considered as a plasticity initiator in regard of Th17 subset *via*  decreasing Foxp3 expression and assisting increased IFN-γ secretion.

In 2011, a hallmark study of Hovhannisyan *et al*[111] showed evidence for Treg/Th17 plasticity in IBD by showing the presence of IL-17 producing, Foxp3 expressing Th cells in inflamed intestinal mucosa from Crohn’s disease patients. Importantly, this population showed suppressor activity *in vitro*. We have gone on to demonstrate the presence of this unique T cell subset in peripheral blood from IBD patients[60] and have found evidence for several types of plasticity including Treg/Th17, Th1/Th17 and Th22/Th17 within the lamina propria of lesions from IBD patients[112].

**CONCLUSION**

Plasticity between Treg and Th17 likely occurs in the context of dynamic changes in the inflammatory milieu. Thus, pro-inflammatory stimuli may promote conversion of immune-suppressive regulatory T cells into pro-inflammatory Th17 cells, while resolution of inflammation may trigger or even require the alternate shift from Th17 to Treg. This concept is just becoming appreciated and requires further study to correlate both causes and outcomes. Targeting plasticity may offer avenues to pharmacologically restore the Th17/Treg balance in the intestine for therapeutic benefit[113]. In addition, targeting plasticity may help improve upon future therapies. Clinical trials of Treg therapy of Crohn’s disease failed[114] perhaps in part due to Treg instability. Further understanding of Treg plasticity may help to augment Treg therapy in the future.

Many studies have implicitly suggested the possibility of plasticity during their experiments and observation of inflammatory processes. It is clear however that several pathways give rise to the heterogeneous populations referred to as Th17 and Treg in the intestine. The field is in part limited due to constraints inherent to the techniques used to analyse these cells. Most investigators rely upon multicolor flow cytometry, requiring the precise selection of surface and intracellular markers and setting of conditions and controls in order to provide limited functional and expression data. New technologies look to overcome these technical issues as well as to enhance the depth of analysis. Examples include deep immune-phenotyping using CYTOF 2 mass spectrometry which allows the analysis of over 100 parameters at the single cell level without dealing with spectral overlap, alone or in combination with single cell transcriptomics.

To conclude, unravelling the complexity that underlies plasticity between Th17 and Treg cells may be key to understanding the intricate pathogenesis of T cell-mediated immune disorders, such as IBD. However, novel approaches and their application to human IBD will be required to reach this objective.

**REFERENCES**

1 **Feldmann M**, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. *Immunol Rev* 2008; **223**: 7-19 [PMID: 18613827 DOI: 10.1111/j.1600-065X.2008.00626.x]

2 **Damsker JM**, Hansen AM, Caspi RR. Th1 and Th17 cells: adversaries and collaborators. *Ann N Y Acad Sci* 2010; **1183**: 211-221 [PMID: 20146717 DOI: 10.1111/j.1749-6632.2009.05133.x]

3 **Kunz M**, Ibrahim SM. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. *Mediators Inflamm* 2009; **2009**: 979258 [PMID: 19884985 DOI: 10.1155/2009/979258]

4 **Mosmann TR**, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986. *J Immunol* 2005; **175**: 5-14 [PMID: 15972624 DOI: 175/1/5]

5 **Ahern PP**, Izcue A, Maloy KJ, Powrie F. The interleukin-23 axis in intestinal inflammation. *Immunol Rev* 2008; **226**: 147-159 [PMID: 19161422 DOI: 10.1111/j.1600-065X.2008.00705.x]

6 **Annunziato F**, Romagnani S. Do studies in humans better depict Th17 cells? *Blood* 2009; **114**: 2213-2219 [PMID: 19494349 DOI: 10.1182/blood-2009-03-209189]

7 **Chen Z**, O'Shea JJ. Th17 cells: a new fate for differentiating helper T cells. *Immunol Res* 2008; **41**: 87-102 [PMID: 18172584 DOI: 10.1007/s12026-007-8014-9]

8 **Fouser LA**, Wright JF, Dunussi-Joannopoulos K, Collins M. Th17 cytokines and their emerging roles in inflammation and autoimmunity. *Immunol Rev* 2008; **226**: 87-102 [PMID: 19161418 DOI: 10.1111/j.1600-065X.2008.00712.x]

9 **Hue S**, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, Powrie F, Maloy KJ. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. *J Exp Med* 2006; **203**: 2473-2483 [PMID: 17030949 DOI: jem.20061099]

10 **Kullberg MC**, Jankovic D, Feng CG, Hue S, Gorelick PL, McKenzie BS, Cua DJ, Powrie F, Cheever AW, Maloy KJ, Sher A. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. *J Exp Med* 2006; **203**: 2485-2494 [PMID: 17030948 DOI: jem.20061082]

11 **Conti HR**, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, Ho AW, Hai JH, Yu JJ, Jung JW, Filler SG, Masso-Welch P, Edgerton M, Gaffen SL. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. *J Exp Med* 2009; **206**: 299-311 [PMID: 19204111 DOI: 10.1084/jem.20081463]

12 **Langrish CL**, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. *Immunol Rev* 2004; **202**: 96-105 [PMID: 15546388 DOI: IMR214]

13 **Lin Y**, Ritchea S, Logar A, Slight S, Messmer M, Rangel-Moreno J, Guglani L, Alcorn JF, Strawbridge H, Park SM, Onishi R, Nyugen N, Walter MJ, Pociask D, Randall TD, Gaffen SL, Iwakura Y, Kolls JK, Khader SA. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. *Immunity* 2009; **31**: 799-810 [PMID: 19853481 DOI: 10.1016/j.immuni.2009.08.025]

14 **Maloy KJ**, Kullberg MC. IL-23 and Th17 cytokines in intestinal homeostasis. *Mucosal Immunol* 2008; **1**: 339-349 [PMID: 19079198 DOI: 10.1038/mi.2008.28]

15 **O'Connor W**, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, Kolls JK, Flavell RA. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. *Nat Immunol* 2009; **10**: 603-609 [PMID: 19448631 DOI: 10.1038/ni.1736]

16 **Ogawa A**, Andoh A, Araki Y, Bamba T, Fujiyama Y. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. *Clin Immunol* 2004; **110**: 55-62 [PMID: 14962796 DOI: 10.1016/j.clim.2003.09.013]

17 **Izcue A**, Hue S, Buonocore S, Arancibia-Cárcamo CV, Ahern PP, Iwakura Y, Maloy KJ, Powrie F. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. *Immunity* 2008; **28**: 559-570 [PMID: 18400195 DOI: 10.1016/j.immuni.2008.02.019]

18 **Lee YK**, Turner H, Maynard CL, Oliver JR, Chen D, Elson CO, Weaver CT. Late developmental plasticity in the T helper 17 lineage. *Immunity* 2009; **30**: 92-107 [PMID: 19119024 DOI: 10.1016/j.immuni.2008.11.005]

19 **Rebhahn JA**, Deng N, Sharma G, Livingstone AM, Huang S, Mosmann TR. An animated landscape representation of CD4+ T-cell differentiation, variability, and plasticity: insights into the behavior of populations versus cells. *Eur J Immunol* 2014; **44**: 2216-2229 [PMID: 24945794 DOI: 10.1002/eji.201444645]

20 **Khader SA**, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen F, Eaton SM, Gaffen SL, Swain SL, Locksley RM, Haynes L, Randall TD, Cooper AM. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. *Nat Immunol* 2007; **8**: 369-377 [PMID: 17351619 DOI: ni1449]

21 **Harbour SN**, Maynard CL, Zindl CL, Schoeb TR, Weaver CT. Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. *Proc Natl Acad Sci U S A* 2015; **112**: 7061-7066 [PMID: 26038559 DOI: 10.1073/pnas.1415675112]

22 **Koenen HJ**, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. *Blood* 2008; **112**: 2340-2352 [PMID: 18617638 DOI: 10.1182/blood-2008-01-133967]

23 **Hori S**, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. *Science* 2003; **299**: 1057-1061 [PMID: 12522256 DOI: 10.1126/science.1079490]

24 **Makita S**, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, Nakamura T, Koganei K, Fukushima T, Watanabe M. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. *J Immunol* 2004; **173**: 3119-3130 [PMID: 15322172 DOI: 173/5/3119]

25 **Mucida D**, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. *Science* 2007; **317**: 256-260 [PMID: 17569825 DOI: 1145697]

26 **Gratz IK**, Campbell DJ. Organ-specific and memory treg cells: specificity, development, function, and maintenance. *Front Immunol* 2014; **5**: 333 [PMID: 25076948 DOI: 10.3389/fimmu.2014.00333]

27 **Fujino S**, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. *Gut* 2003; **52**: 65-70 [PMID: 12477762]

28 **Yang XO**, Chang SH, Park H, Nurieva R, Shah B, Acero L, Wang YH, Schluns KS, Broaddus RR, Zhu Z, Dong C. Regulation of inflammatory responses by IL-17F. *J Exp Med* 2008; **205**: 1063-1075 [PMID: 18411338 DOI: 10.1084/jem.20071978]

29 **Blaschitz C**, Raffatellu M. Th17 cytokines and the gut mucosal barrier. *J Clin Immunol* 2010; **30**: 196-203 [PMID: 20127275 DOI: 10.1007/s10875-010-9368-7]

30 **Ciofani M**, Madar A, Galan C, Sellars M, Mace K, Pauli F, Agarwal A, Huang W, Parkurst CN, Muratet M, Newberry KM, Meadows S, Greenfield A, Yang Y, Jain P, Kirigin FK, Birchmeier C, Wagner EF, Murphy KM, Myers RM, Bonneau R, Littman DR. A validated regulatory network for Th17 cell specification. *Cell* 2012; **151**: 289-303 [PMID: 23021777 DOI: 10.1016/j.cell.2012.09.016]

31 **Jostins L**, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Buning C, Cohain A, Cichon S, D'Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H, International IBD Genetics Consortium (IIBDGC), Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease*. Nature* 2012; **491**: 119-124 [PMID: 23128233 DOI: 10.1038/nature11582]

32 **Wu C**, Yosef N, Thalhamer T, Zhu C, Xiao S, Kishi Y, Regev A, Kuchroo VK. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. *Nature* 2013; **496**: 513-517 [PMID: 23467085 DOI: 10.1038/nature11984]

33 **Dang EV**, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, Bordman Z, Fu J, Kim Y, Yen HR, Luo W, Zeller K, Shimoda L, Topalian SL, Semenza GL, Dang CV, Pardoll DM, Pan F. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. *Cell* 2011; **146**: 772-784 [PMID: 21871655 DOI: 10.1016/j.cell.2011.07.033]

34 **de Beaucoudrey L**, Puel A, Filipe-Santos O, Cobat A, Ghandil P, Chrabieh M, Feinberg J, von Bernuth H, Samarina A, Jannière L, Fieschi C, Stéphan JL, Boileau C, Lyonnet S, Jondeau G, Cormier-Daire V, Le Merrer M, Hoarau C, Lebranchu Y, Lortholary O, Chandesris MO, Tron F, Gambineri E, Bianchi L, Rodriguez-Gallego C, Zitnik SE, Vasconcelos J, Guedes M, Vitor AB, Marodi L, Chapel H, Reid B, Roifman C, Nadal D, Reichenbach J, Caragol I, Garty BZ, Dogu F, Camcioglu Y, Gülle S, Sanal O, Fischer A, Abel L, Stockinger B, Picard C, Casanova JL. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. *J Exp Med* 2008; **205**: 1543-1550 [PMID: 18591412 DOI: 10.1084/jem.20080321]

35 **Ivanov II**, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. *Cell* 2006; **126**: 1121-1133 [PMID: 16990136 DOI: S0092-8674(06)01105-6]

36 **Bettelli E**, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. *Nature* 2006; **441**: 235-238 [PMID: 16648838 DOI: nature04753]

37 **Mangan PR**, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces development of the T(H)17 lineage. *Nature* 2006; **441**: 231-234 [PMID: 16648837 DOI: nature04754]

38 **Veldhoen M**, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. *Immunity* 2006; **24**: 179-189 [PMID: 16473830 DOI: S1074-7613(06)00004-5]

39 **Sutton C**, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. *J Exp Med* 2006; **203**: 1685-1691 [PMID: 16818675 DOI: jem.20060285]

40 **Nurieva R**, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, Dong C. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. *Nature* 2007; **448**: 480-483 [PMID: 17581589 DOI: nature05969]

41 **Cargill M**, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ, Leong DU, Panko JM, McAllister LB, Hansen CB, Papenfuss J, Prescott SM, White TJ, Leppert MF, Krueger GG, Begovich AB. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. *Am J Hum Genet* 2007; **80**: 273-290 [PMID: 17236132 DOI: S0002-9297(07)62685-8]

42 **Wellcome Trust Case Control Consortium**, Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, McCarthy MI, Ouwehand WH, Samani NJ, Todd JA, Donnelly P, Barrett JC, Davison D, Easton D, Evans DM, Leung HT, Marchini JL, Morris AP, Spencer CC, Tobin MD, Attwood AP, Boorman JP, Cant B, Everson U, Hussey JM, Jolley JD, Knight AS, Koch K, Meech E, Nutland S, Prowse CV, Stevens HE, Taylor NC, Walters GR, Walker NM, Watkins NA, Winzer T, Jones RW, McArdle WL, Ring SM, Strachan DP, Pembrey M, Breen G, St Clair D, Caesar S, Gordon-Smith K, Jones L, Fraser C, Green EK, Grozeva D, Hamshere ML, Holmans PA, Jones IR, Kirov G, Moskivina V, Nikolov I, O'Donovan MC, Owen MJ, Collier DA, Elkin A, Farmer A, Williamson R, McGuffin P, Young AH, Ferrier IN, Ball SG, Balmforth AJ, Barrett JH, Bishop TD, Iles MM, Maqbool A, Yuldasheva N, Hall AS, Braund PS, Dixon RJ, Mangino M, Stevens S, Thompson JR, Bredin F, Tremelling M, Parkes M, Drummond H, Lees CW, Nimmo ER, Satsangi J, Fisher SA, Forbes A, Lewis CM, Onnie CM, Prescott NJ, Sanderson J, Matthew CG, Barbour J, Mohiuddin MK, Todhunter CE, Mansfield JC, Ahmad T, Cummings FR, Jewell DP, Webster J, Brown MJ, Lathrop MG, Connell J, Dominiczak A, Marcano CA, Burke B, Dobson R, Gungadoo J, Lee KL, Munroe PB, Newhouse SJ, Onipinla A, Wallace C, Xue M, Caulfield M, Farrall M, Barton A, Biologics in RA Genetics and Genomics Study Syndicate (BRAGGS) Steering Committee, Bruce IN, Donovan H, Eyre S, Gilbert PD, Hilder SL, Hinks AM, John SL, Potter C, Silman AJ, Symmons DP, Thomson W, Worthington J, Dunger DB, Widmer B, Frayling TM, Freathy RM, Lango H, Perry JR, Shields BM, Weedon MN, Hattersley AT, Hitman GA, Walker M, Elliott KS, Groves CJ, Lindgren CM, Rayner NW, Timpson NJ, Zeggini E, Newport M, Sirugo G, Lyons E, Vannberg F, Hill AV, Bradbury LA, Farrar C, Pointon JJ, Wordsworth P, Brown MA, Franklyn JA, Heward JM, Simmonds MJ, Gough SC, Seal S, Breast Cancer Susceptibility Collaboration (UK), Stratton MR, Rahman N, Ban M, Goris A, Sawcer SJ, Compston A, Conway D, Jallow M, Newport M, Sirugo G, Rockett KA, Bumpstead SJ, Chaney A, Downes K, Ghori MJ, Gwilliam R, Hunt SE, Inouye M, Keniry A, King E, McGinnis R, Potter S, Ravindrarajah R, Whittaker P, Widden C, Withers D, Cardin NJ, Davison D, Ferreira T, Pereira-Gale J, Hallgrimsdo'ttir IB, Howie BN, Su Z, Teo YY, Vukcevic D, Bentley D, Brown MA, Compston A, Farrall M, Hall AS, Hattersley AT, Hill AV, Parkes M, Pembrey M, Stratton MR, Mitchell SL, Newby PR, Brand OJ, Carr-Smith J, Pearce SH, McGinnis R, Keniry A, Deloukas P, Reveille JD, Zhou X, Sims AM, Dowling A, Taylor J, Doan T, Davis JC, Savage L, Ward MM, Learch TL, Weisman MH, Brown M. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants*. Nat Genet* 2007; **39**: 1329-1337 [PMID: 17952073]

43 **Wellcome Trust Case Control Consortium**. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 2007; **447**: 661-678 [PMID: 17554300 DOI: nature05911]

44 **Duerr RH**, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science* 2006; **314**: 1461-1463 [PMID: 17068223 DOI: 1135245]

45 **Li LJ**, Gong C, Zhao MH, Feng BS. Role of interleukin-22 in inflammatory bowel disease. *World J Gastroenterol* 2014; **20**: 18177-18188 [PMID: 25561785 DOI: 10.3748/wjg.v20.i48.18177]

46 **Hueber W**, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. *Gut* 2012; **61**: 1693-1700 [PMID: 22595313 DOI: 10.1136/gutjnl-2011-301668]

47 **O'Shea JJ**, Kanno Y, Chan AC. In search of magic bullets: the golden age of immunotherapeutics. *Cell* 2014; **157**: 227-240 [PMID: 24679538 DOI: 10.1016/j.cell.2014.03.010]

48 **Josefowicz SZ**, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. *Annu Rev Immunol* 2012; **30**: 531-564 [PMID: 22224781 DOI: 10.1146/annurev.immunol.25.022106.141623]

49 **Kang SG**, Lim HW, Andrisani OM, Broxmeyer HE, Kim CH. Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells. *J Immunol* 2007; **179**: 3724-3733 [PMID: 17785809 DOI: 179/6/3724]

50 **Zhou L**, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF, Littman DR. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. *Nature* 2008; **453**: 236-240 [PMID: 18368049 DOI: 10.1038/nature06878]

51 **Yang KL**, Chang WT, Hung KC, Li EI, Chuang CC. Inhibition of transforming growth factor-beta-induced liver fibrosis by a retinoic acid derivative via the suppression of Col 1A2 promoter activity. *Biochem Biophys Res Commun* 2008; **373**: 219-223 [PMID: 18558083 DOI: 10.1016/j.bbrc.2008.05.192]

52 **Martinez GJ**, Zhang Z, Reynolds JM, Tanaka S, Chung Y, Liu T, Robertson E, Lin X, Feng XH, Dong C. Smad2 positively regulates the generation of Th17 cells. *J Biol Chem* 2010; **285**: 29039-29043 [PMID: 20667820 DOI: 10.1074/jbc.C110.155820]

53 **Goto Y**, Panea C, Nakato G, Cebula A, Lee C, Diez MG, Laufer TM, Ignatowicz L, Ivanov II. Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation. *Immunity* 2014; **40**: 594-607 [PMID: 24684957 DOI: 10.1016/j.immuni.2014.03.005]

54 **Atarashi K**, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, Fukuda S, Saito T, Narushima S, Hase K, Kim S, Fritz JV, Wilmes P, Ueha S, Matsushima K, Ohno H, Olle B, Sakaguchi S, Taniguchi T, Morita H, Hattori M, Honda K. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. *Nature* 2013; **500**: 232-236 [PMID: 23842501 DOI: 10.1038/nature12331]

55 **Geuking MB**, Cahenzli J, Lawson MA, Ng DC, Slack E, Hapfelmeier S, McCoy KD, Macpherson AJ. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. *Immunity* 2011; **34**: 794-806 [PMID: 21596591 DOI: 10.1016/j.immuni.2011.03.021]

56 **Livingston M**, Loach D, Wilson M, Tannock GW, Baird M. Gut commensal Lactobacillus reuteri 100-23 stimulates an immunoregulatory response. *Immunol Cell Biol* 2010; **88**: 99-102 [PMID: 19786979 DOI: 10.1038/icb.2009.71]

57 **Singh N**, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, Thangaraju M, Prasad PD, Manicassamy S, Munn DH, Lee JR, Offermanns S, Ganapathy V. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. *Immunity* 2014; **40**: 128-139 [PMID: 24412617 DOI: 10.1016/j.immuni.2013.12.007]

58 **Arpaia N**, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ, Rudensky AY. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature* 2013; **504**: 451-455 [PMID: 24226773 DOI: 10.1038/nature12726]

59 **Round JL**, Lee SM, Li J, Tran G, Jabri B, Chatila TA, Mazmanian SK. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. *Science* 2011; **332**: 974-977 [PMID: 21512004 DOI: 10.1126/science.1206095]

60 **Ueno A**, Jijon H, Chan R, Ford K, Hirota C, Kaplan GG, Beck PL, Iacucci M, Fort Gasia M, Barkema HW, Panaccione R, Ghosh S. Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. *Inflamm Bowel Dis* 2013; **19**: 2522-2534 [PMID: 24097227 DOI: 10.1097/MIB.0b013e3182a85709]

61 **Basu R**, Whitley SK, Bhaumik S, Zindl CL, Schoeb TR, Benveniste EN, Pear WS, Hatton RD, Weaver CT. IL-1 signaling modulates activation of STAT transcription factors to antagonize retinoic acid signaling and control the TH17 cell-iTreg cell balance. *Nat Immunol* 2015; **16**: 286-295 [PMID: 25642823 DOI: 10.1038/ni.3099]

62 **Zhang L**, Yuan S, Cheng G, Guo B. Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. *PLoS One* 2011; **6**: e28432 [PMID: 22163016 DOI: 10.1371/journal.pone.0028432]

63 **Yang L**, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, Kuchroo VK, Hafler DA. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. *Nature* 2008; **454**: 350-352 [PMID: 18469800 DOI: 10.1038/nature07021]

64 **Fantini MC**, Rizzo A, Fina D, Caruso R, Becker C, Neurath MF, Macdonald TT, Pallone F, Monteleone G. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. *Eur J Immunol* 2007; **37**: 3155-3163 [PMID: 17918200 DOI: 10.1002/eji.200737766]

65 **Peluso I**, Fantini MC, Fina D, Caruso R, Boirivant M, MacDonald TT, Pallone F, Monteleone G. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. *J Immunol* 2007; **178**: 732-739 [PMID: 17202333 DOI: 178/2/732]

66 **Sugimoto K**, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, Blumberg RS, Xavier RJ, Mizoguchi A. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. *J Clin Invest* 2008; **118**: 534-544 [PMID: 18172556 DOI: 10.1172/JCI33194]

67 **Zenewicz LA**, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. *Immunity* 2008; **29**: 947-957 [PMID: 19100701 DOI: 10.1016/j.immuni.2008.11.003]

68 **Awasthi A**, Riol-Blanco L, Jäger A, Korn T, Pot C, Galileos G, Bettelli E, Kuchroo VK, Oukka M. Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. *J Immunol* 2009; **182**: 5904-5908 [PMID: 19414740 DOI: 10.4049/jimmunol.0900732]

69 **Coccia M**, Harrison OJ, Schiering C, Asquith MJ, Becher B, Powrie F, Maloy KJ. IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. *J Exp Med* 2012; **209**: 1595-1609 [PMID: 22891275 DOI: 10.1084/jem.20111453]

70 **Mudter J**, Yu J, Zufferey C, Brüstle A, Wirtz S, Weigmann B, Hoffman A, Schenk M, Galle PR, Lehr HA, Mueller C, Lohoff M, Neurath MF. IRF4 regulates IL-17A promoter activity and controls RORγt-dependent Th17 colitis in vivo. *Inflamm Bowel Dis* 2011; **17**: 1343-1358 [PMID: 21305677 DOI: 10.1002/ibd.21476]

71 **Huber M**, Lohoff M. IRF4 at the crossroads of effector T-cell fate decision. *Eur J Immunol* 2014; **44**: 1886-1895 [PMID: 24782159 DOI: 10.1002/eji.201344279]

72 **Vasanthakumar A**, Moro K, Xin A, Liao Y, Gloury R, Kawamoto S, Fagarasan S, Mielke LA, Afshar-Sterle S, Masters SL, Nakae S, Saito H, Wentworth JM, Li P, Liao W, Leonard WJ, Smyth GK, Shi W, Nutt SL, Koyasu S, Kallies A. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. *Nat Immunol* 2015; **16**: 276-285 [PMID: 25599561 DOI: 10.1038/ni.3085]

73 **Punkenburg E**, Vogler T, Büttner M, Amann K, Waldner M, Atreya R, Abendroth B, Mudter J, Merkel S, Gallmeier E, Rose-John S, Neurath MF, Hildner K. Batf-dependent Th17 cells critically regulate IL-23 driven colitis-associated colon cancer. *Gut* 2015 Apr 2; Epub ahead of print [PMID: 25838550 DOI: gutjnl-2014-308227]

74 **Quintana FJ**, Jin H, Burns EJ, Nadeau M, Yeste A, Kumar D, Rangachari M, Zhu C, Xiao S, Seavitt J, Georgopoulos K, Kuchroo VK. Aiolos promotes TH17 differentiation by directly silencing Il2 expression. *Nat Immunol* 2012; **13**: 770-777 [PMID: 22751139 DOI: 10.1038/ni.2363]

75 **Raffin C**, Pignon P, Celse C, Debien E, Valmori D, Ayyoub M. Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1β by downregulating their suppressor functions. *J Immunol* 2013; **191**: 4619-4627 [PMID: 24068664 DOI: 10.4049/jimmunol.1301378]

76 **Liu HP**, Cao AT, Feng T, Li Q, Zhang W, Yao S, Dann SM, Elson CO, Cong Y. TGF-β converts Th1 cells into Th17 cells through stimulation of Runx1 expression. *Eur J Immunol* 2015; **45**: 1010-1018 [PMID: 25605286 DOI: 10.1002/eji.201444726]

77 **Nakayamada S**, Takahashi H, Kanno Y, O'Shea JJ. Helper T cell diversity and plasticity. *Curr Opin Immunol* 2012; **24**: 297-302 [PMID: 22341735 DOI: 10.1016/j.coi.2012.01.014]

78 **Baumjohann D**, Ansel KM. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. *Nat Rev Immunol* 2013; **13**: 666-678 [PMID: 23907446 DOI: 10.1038/nri3494]

79 **O'Neill LA**, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signalling. *Nat Rev Immunol* 2011; **11**: 163-175 [PMID: 21331081 DOI: 10.1038/nri2957]

80 **Brain O**, Owens BM, Pichulik T, Allan P, Khatamzas E, Leslie A, Steevels T, Sharma S, Mayer A, Catuneanu AM, Morton V, Sun MY, Jewell D, Coccia M, Harrison O, Maloy K, Schönefeldt S, Bornschein S, Liston A, Simmons A. The intracellular sensor NOD2 induces microRNA-29 expression in human dendritic cells to limit IL-23 release. *Immunity* 2013; **39**: 521-536 [PMID: 24054330 DOI: 10.1016/j.immuni.2013.08.035]

81 **Wang H**, Flach H, Onizawa M, Wei L, McManus MT, Weiss A. Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. *Nat Immunol* 2014; **15**: 393-401 [PMID: 24608041 DOI: 10.1038/ni.2846]

82 **Nakahama T**, Hanieh H, Nguyen NT, Chinen I, Ripley B, Millrine D, Lee S, Nyati KK, Dubey PK, Chowdhury K, Kawahara Y, Kishimoto T. Aryl hydrocarbon receptor-mediated induction of the microRNA-132/212 cluster promotes interleukin-17-producing T-helper cell differentiation. *Proc Natl Acad Sci U S A* 2013; **110**: 11964-11969 [PMID: 23818645 DOI: 10.1073/pnas.1311087110]

83 **Kroesen BJ**, Teteloshvili N, Smigielska-Czepiel K, Brouwer E, Boots AM, van den Berg A, Kluiver J. Immuno-miRs: critical regulators of T-cell development, function and ageing. *Immunology* 2015; **144**: 1-10 [PMID: 25093579 DOI: 10.1111/imm.12367]

84 **Kouri RR**, Ratrie H, Atlas SA, Niwa A, Nebert DW. Aryl hydrocarbon hydroxylase induction in human lymphocyte cultures by 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Life Sci* 1974; **15**: 1585-1595 [PMID: 4549995]

85 **Mason ME**, Okey AB. Aryl hydrocarbon hydroxylase activity in mouse, rat, and human mammary tumors. *Cancer Res* 1981; **41**: 2778-2782 [PMID: 6265068]

86 **Okey AB**, Riddick DS, Harper PA. The Ah receptor: mediator of the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. *Toxicol Lett* 1994; **70**: 1-22 [PMID: 8310450 DOI: 0378-4274(94)90139-2]

87 **Marshall NB**, Kerkvliet NI. Dioxin and immune regulation: emerging role of aryl hydrocarbon receptor in the generation of regulatory T cells. *Ann N Y Acad Sci* 2010; **1183**: 25-37 [PMID: 20146706 DOI: 10.1111/j.1749-6632.2009.05125.x]

88 **Esser C**, Rannug A, Stockinger B. The aryl hydrocarbon receptor in immunity. *Trends Immunol* 2009; **30**: 447-454 [PMID: 19699679 DOI: 10.1016/j.it.2009.06.005]

89 **Quintana FJ**, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, Caccamo M, Oukka M, Weiner HL. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. *Nature* 2008; **453**: 65-71 [PMID: 18362915 DOI: 10.1038/nature06880]

90 **Veldhoen M**, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, Stockinger B. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. *Nature* 2008; **453**: 106-109 [PMID: 18362914 DOI: 10.1038/nature06881]

91 **Kimura A**, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. *Proc Natl Acad Sci U S A* 2008; **105**: 9721-9726 [PMID: 18607004 DOI: 10.1073/pnas.0804231105]

92 **Veldhoen M**, Hirota K, Christensen J, O'Garra A, Stockinger B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. *J Exp Med* 2009; **206**: 43-49 [PMID: 19114668 DOI: 10.1084/jem.20081438]

93 **Hauben E**, Gregori S, Draghici E, Migliavacca B, Olivieri S, Woisetschläger M, Roncarolo MG. Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. *Blood* 2008; **112**: 1214-1222 [PMID: 18550851 DOI: 10.1182/blood-2007-08-109843]

94 **Mezrich JD**, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. *J Immunol* 2010; **185**: 3190-3198 [PMID: 20720200 DOI: 10.4049/jimmunol.0903670]

95 **Nguyen NT**, Nakahama T, Le DH, Van Son L, Chu HH, Kishimoto T. Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. *Front Immunol* 2014; **5**: 551 [PMID: 25400638 DOI: 10.3389/fimmu.2014.00551]

96 **Moura-Alves P**, Faé K, Houthuys E, Dorhoi A, Kreuchwig A, Furkert J, Barison N, Diehl A, Munder A, Constant P, Skrahina T, Guhlich-Bornhof U, Klemm M, Koehler AB, Bandermann S, Goosmann C, Mollenkopf HJ, Hurwitz R, Brinkmann V, Fillatreau S, Daffe M, Tümmler B, Kolbe M, Oschkinat H, Krause G, Kaufmann SH. AhR sensing of bacterial pigments regulates antibacterial defence. *Nature* 2014; **512**: 387-392 [PMID: 25119038 DOI: 10.1038/nature13684]

97 **Lee BM**, Mahadevan LC. Stability of histone modifications across mammalian genomes: implications for 'epigenetic' marking. *J Cell Biochem* 2009; **108**: 22-34 [PMID: 19623574 DOI: 10.1002/jcb.22250]

98 **Wei G**, Wei L, Zhu J, Zang C, Hu-Li J, Yao Z, Cui K, Kanno Y, Roh TY, Watford WT, Schones DE, Peng W, Sun HW, Paul WE, O'Shea JJ, Zhao K. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. *Immunity* 2009; **30**: 155-167 [PMID: 19144320 DOI: 10.1016/j.immuni.2008.12.009]

99 **Rowell E**, Wilson CB. Programming perpetual T helper cell plasticity. *Immunity* 2009; **30**: 7-9 [PMID: 19144312 DOI: 10.1016/j.immuni.2008.12.012]

100 **Xiang Y**, Zhu Z, Han G, Lin H, Xu L, Chen CD. JMJD3 is a histone H3K27 demethylase. *Cell Res* 2007; **17**: 850-857 [PMID: 17923864 DOI: cr200783]

101 **Li Q**, Zou J, Wang M, Ding X, Chepelev I, Zhou X, Zhao W, Wei G, Cui J, Zhao K, Wang HY, Wang RF. Critical role of histone demethylase Jmjd3 in the regulation of CD4+ T-cell differentiation. *Nat Commun* 2014; **5**: 5780 [PMID: 25531312 DOI: 10.1038/ncomms6780]

102 **Esposito M**, Ruffini F, Bergami A, Garzetti L, Borsellino G, Battistini L, Martino G, Furlan R. IL-17- and IFN-γ-secreting Foxp3+ T cells infiltrate the target tissue in experimental autoimmunity. *J Immunol* 2010; **185**: 7467-7473 [PMID: 21098230 DOI: 10.4049/jimmunol.1001519]

103 **Zhou L**, Chong MM, Littman DR. Plasticity of CD4+ T cell lineage differentiation. *Immunity* 2009; **30**: 646-655 [PMID: 19464987 DOI: 10.1016/j.immuni.2009.05.001]

104 **Nistala K**, Adams S, Cambrook H, Ursu S, Olivito B, de Jager W, Evans JG, Cimaz R, Bajaj-Elliott M, Wedderburn LR. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. *Proc Natl Acad Sci U S A* 2010; **107**: 14751-14756 [PMID: 20679229 DOI: 10.1073/pnas.1003852107]

105 **Korn T**, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. *Annu Rev Immunol* 2009; **27**: 485-517 [PMID: 19132915 DOI: 10.1146/annurev.immunol.021908.132710]

106 **Globig AM**, Hennecke N, Martin B, Seidl M, Ruf G, Hasselblatt P, Thimme R, Bengsch B. Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-γ+IL-17+coproducing CD4+ T cells in active inflammatory bowel disease. *Inflamm Bowel Dis* 2014; **20**: 2321-2329 [PMID: 25248005 DOI: 10.1097/MIB.0000000000000210]

107 **Singh K**, Gatzka M, Peters T, Borkner L, Hainzl A, Wang H, Sindrilaru A, Scharffetter-Kochanek K. Reduced CD18 levels drive regulatory T cell conversion into Th17 cells in the CD18hypo PL/J mouse model of psoriasis. *J Immunol* 2013; **190**: 2544-2553 [PMID: 23418628 DOI: 10.4049/jimmunol.1202399]

108 **Gagliani N**, Vesely MC, Iseppon A, Brockmann L, Xu H, Palm NW, de Zoete MR, Licona-Limón P, Paiva RS, Ching T, Weaver C, Zi X, Pan X, Fan R, Garmire LX, Cotton MJ, Drier Y, Bernstein B, Geginat J, Stockinger B, Esplugues E, Huber S, Flavell RA. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. *Nature* 2015; **523**: 221-225 [PMID: 25924064 DOI: 10.1038/nature14452]

109 **Barnes MJ**, Powrie F. Regulatory T cells reinforce intestinal homeostasis. *Immunity* 2009; **31**: 401-411 [PMID: 19766083 DOI: 10.1016/j.immuni.2009.08.011]

110 **Morrison PJ**, Ballantyne SJ, Kullberg MC. Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity. *Immunology* 2011; **133**: 397-408 [PMID: 21631495 DOI: 10.1111/j.1365-2567.2011.03454.x]

111 **Hovhannisyan Z**, Treatman J, Littman DR, Mayer L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. *Gastroenterology* 2011; **140**: 957-965 [PMID: 21147109 DOI: 10.1053/j.gastro.2010.12.002]

112 **Li J**, Ueno A, Fort Gasia M, Hirota C, Deane M, Chan R, Iacucci M, Kaplan G, Panaccione R, Luider J, Wang T, Tom M, Qian JM, Gui X, Ghosh S. Distinctive Th17 Lymphocyte Plasticity in Intestinal Lamina Propria of IBD Patients Compared With Healthy Controls. *Gastoroenterology* 2015; **148**: S323 [DOI: 10.1016/S0016-5085(15)31070-2]


113 **Eisenstein EM**, Williams CB. The T(reg)/Th17 cell balance: a new paradigm for autoimmunity. *Pediatr Res* 2009; **65**: 26R-31R [PMID: 19218879 DOI: 10.1203/PDR.0b013e31819e76c7]

114 **Desreumaux P**, Foussat A, Allez M, Beaugerie L, Hébuterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N, Ticchioni M, Duchange A, Morel-Mandrino P, Neveu V, Clerget-Chossat N, Forte M, Colombel JF. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. *Gastroenterology* 2012; **143**: 1207-17.e1-2 [PMID: 22885333 DOI: 10.1053/j.gastro.2012.07.116]


115 **Brüstle A**, Heink S, Huber M, Rosenplänter C, Stadelmann C, Yu P, Arpaia E, Mak TW, Kamradt T, Lohoff M. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. *Nat Immunol* 2007; **8**: 958-966 [PMID: 17676043 DOI: ni1500]

116 **Schraml BU**, Hildner K, Ise W, Lee WL, Smith WA, Solomon B, Sahota G, Sim J, Mukasa R, Cemerski S, Hatton RD, Stormo GD, Weaver CT, Russell JH, Murphy TL, Murphy KM. The AP-1 transcription factor Batf controls T(H)17 differentiation. *Nature* 2009; **460**: 405-409 [PMID: 19578362 DOI: 10.1038/nature08114]

**P-Reviewer:** Gardlik R, Kuo SM **S-Editor:** Yu J **L-Editor:** **E-Editor:**



**Figure 1 The concept of Th17 plasticity.** The Foxp3 expressing Treg subset either develops naturally (nTreg) or is peripherally induced from naïve T cells (iTreg). Th17 generating factors including cytokines, transcription factors, and other molecular cues can induce these cells to differentiate into transitional cells with co-expression of Foxp3 and RORc. Th17 cells may be converted into Th17/1-transitional cells with co-expression of RORc and TBX21.



**Figure 2 The factors influencing the plasticity between Treg and Th17 subsets.** Cytokines and growth factors (shown in blue letters) may trigger transdifferentiation of the pre-committed Foxp3 expressing Treg population to RORc expressing cells. Micro RNAs (miR, shown in red letters) play a pivotal role in differentially regulating Treg/Th17 plasticity. Transcription factors (aqua ovals) direct the plasticity by positively or negatively controlling Foxp3 and/or RORc expression. The aryl hydrocarbon receptor (AhR, green circle) can promote distinct differentiation pathways in response to two pathway-specific ligands (TCDD and FICZ, Green circles) resulting in either augmentation of Foxp3 or RORc, respectively.

**Table 1 Cytokines related to Th17 development and plasticity in human**

|  |  |  |
| --- | --- | --- |
| **Cytokine** | **Effect** | **References** |
| IL-1β | Accelerate IL-17A secretion from IL-17 secreting Innate  Lymphoid Cells and Th17 | [69] |
| IL-6 | Induce autocrine IL-21 and generation of Th17 | [20] |
| IL-10 | Suppress IL-17A and Th17 generation | [62] |
| IL-12 | Induce IFN-γ secretion from Th17 cells (Th1/Th17 plasticity) | [20] |
| IL-21 | Potentiates pathogenic effects of Th17 cells in the gut | [64, 65] |
| IL-22 | Attenuate the development of intestinal pathology *via*  Stat3-mediated effects on epithelial cells | [66, 67] |
| IL-23 | Induce IL-22 and IL-17A secretions and maintain Th17 expansion | [68] |
| TGF-β1 | Initiate generation of Treg and Th17 populations dependent on the concentration | [63] |

**Table 2 Transcription factors related to Th17 development and plasticity**

|  |  |  |
| --- | --- | --- |
| **Transcription Factor** | **Effect** | **References** |
| Fosl2 | A key determinant of cellular plasticity | [30] |
| IRF4 | Th17 differentiation *via*  RORγt dependent and independent pathways | [115] |
| Augmented in patients with IBD and correlated with enhanced production of *IL17* and *IL22* mRNA | [70] |
| BATF | Required for differentiation of Th17 *via*  induction of RORγt, and bound to *Il17, Il21 and Il22* promoters | [116] |
| BATF+ RORc- Th17 cells are found in gut tissues from UC but not CD patients. | [73] |
| HIF-1 | A key transregulator of Th17 polarization and suppressor of Foxp3 in Treg | [33, 81] |
| Reciprocal regulation between HIF-1 and miR210 | [81] |
| Jmjd3 | H3K27 demethylase, important for Th1/Th17 plasticity | [101] |
| RORc (human) RORγt (mouse) | Essential for Th17 differentiation induced by TGF-β1 and IL-6 or IL-21 | [35] |
| IKZF3 (Aiolos) | Promotes Th17 differentiation *via*  silencing of the *Il2* locus | [74] |
| Aiolos+ iTreg respond to IL-1β and downregulate their suppressor functions | [75] |

**Table 3 Micro RNAs influencing Th17 development and plasticity**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Micro RNA** | **Inducer** | **Target** | **Effect** | **Reference** |
| miR10 | TGF-β | Bcl-6 | Limit Th17, convert Th cells into Treg | [78, 83] |
| miR17~92 cluster |  | Creb1, TGF-βRII, KZF4 (miR17), PTEN (miR19) | Accumulation of antigen-specific iTreg development, IL-10 production, and possibly Treg cell migration | [78, 83] |
| miR29 | NOD2 | IL-12p40, IL-23p19 | Inhibit IL-23R signalling | [80] |
| miR126 |  | PIK3R2 | Treg-mediated Immunosuppression | [83] |
| miR132/212 cluster | TCDD, FICZ | Bcl-6 | Enhance Th17 development *via*  AhR pathway | [82, 83] |
| miR146a | TLR2-5 | STAT1 | Block Th1 development | [78, 79] |
| miR155 | TLR2-4, TLR9 | SOCS1 | Unleash STAT1, 4, and 5 signals, and promote Th1, Th2, and Treg | [78, 79] |
| miR210 |  | HIF-1 (counter regulator) | Control Foxp3 expression | [81, 83] |
| miR301 |  | PIAS3 | Unleash STAT3 signal, and generate Th17 | [78] |
| miR326 |  | EST-1 | Critical for Th17 development | [78] |